Literature DB >> 25080208

Rituximab in a B cell-driven regimen for the treatment of recurrent membranoproliferative glomerulonephritis after kidney transplantation.

Igor Denizarde Bacelar Marques1, Janaina Ramalho, Daísa Ribeiro David, William Carlos Nahas, Elias David-Neto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25080208     DOI： 10.1007/s11255-014-0792-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  5 in total

1.  Rituximab therapy for Type I membranoproliferative glomerulonephritis.

Authors:  John J Dillon; Michelle Hladunewich; William E Haley; Heather N Reich; Daniel C Cattran; Fernando C Fervenza
Journal:  Clin Nephrol       Date:  2012-04       Impact factor: 0.975

2.  Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.

Authors:  Elsa Guiard; Alexandre Karras; Emmanuelle Plaisier; Jean-Paul Duong Van Huyen; Fadi Fakhouri; Jean-Philippe Rougier; Laure-Hélène Noel; Patrice Callard; Michel Delahousse; Pierre Ronco
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 8.237

3.  Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab.

Authors:  M J Pérez-Sáez; K Toledo; M D Navarro; M Lopez-Andreu; M D Redondo; R Ortega; C Pérez-Seoane; M L Agüera; A Rodríguez-Benot; P Aljama
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

4.  Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.

Authors:  Paolo Cravedi; Piero Ruggenenti; Maria Chiara Sghirlanzoni; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

Review 5.  A review of the current use of rituximab in autoimmune diseases.

Authors:  Hakan M Gürcan; Derin B Keskin; Joel N H Stern; Matthew A Nitzberg; Haris Shekhani; A Razzaque Ahmed
Journal:  Int Immunopharmacol       Date:  2008-11-08       Impact factor: 4.932
  5 in total
  1 in total

Review 1.  Diseases of complement dysregulation-an overview.

Authors:  Edwin K S Wong; David Kavanagh
Journal:  Semin Immunopathol       Date:  2018-01-11       Impact factor: 9.623
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.